

Special Issue

Prevention of Human Papillomavirus (HPV) and Vaccination

Message from the Guest Editors

This Special Issue aims to provide evidence regarding HPV vaccination and screening results and impact in different countries and settings (adolescents, healthy and treated women, men, MSM, etc.). In this Special Issue, original research articles and reviews are welcome on research areas that may include (but are not limited to) the following: HPV genotype distribution in different pathologies according to age and sex, current and future HPV vaccination and screening strategies, efficacy and effectiveness of HPV vaccines in different target populations, measurement of HPV vaccination coverage, HPV vaccination after treatment, vaccine hesitancy, strategies to improve HPV vaccination and screening coverage in different target populations, cost-effectiveness of HPV vaccination and screening, and the use of potentially new and simplified diagnostic tests to evaluate preventive programs' performance. We look forward to receiving your contributions.

Guest Editors

Dr. Sara Boccalini
Prof. Dr. Paolo Bonanni
Dr. Angela Bechini

Deadline for manuscript submissions

31 July 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/219057

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).